IRF2 and colorectal carcinoma: CRC-derived sEVs containing IRF-2 (interferon regulatory factor 2) have been postulated to stimulate VEGF-C (vascular endothelial growth factor C) secretion, resulting in lymphangiogenesis and metastasis [36].